Reduced-Intensity Chemotherapy for Lower-Risk Myelodysplastic Syndromes

Decitabine showed improved responses compared with azacitidine when each was given only on the first 3 days treatment cycle.

The hypomethylating agents (HMA) decitabine and azacitidine are standards of care for high-risk myelodysplastic syndromes (MDS), with treatment administered on the first 5 to 7 days of each 28-day cycle. Investigators now report long-term follow-up of a phase 2 multicenter trial of reduced-intensity therapy in patients with low- and low-intermediate risk MDS (as defined by the International Prognostic Scoring System [IPSS]) who had not received prior HMA treatment.

Patients were randomized to decitabine 20 mg/m² IV or azacitidine 75 mg/m² IV or subcutaneously on days 1 to 3 of 28-day cycles, with treatment continued indefinitely in responding patients. A response-adaptive randomization was employed; as the initial 20-patient cohort showed hi…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Reduced-Intensity Chemotherapy for Lower-Risk Myelodysplastic Syndromes

Topics

Reviewing Author